FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308406944> ?p ?o ?g. }

• W4308406944 abstract "<h3>Background</h3> CV8102 is a non-coding, non-capped RNA complexed with a carrier peptide activating the innate (via TLR7/8, RIG-I) and adaptive immune system. An ongoing phase I trial (CV-8102-008) is investigating intratumoral administration of CV8102 either as a single agent or in combination with systemic anti-PD-1 antibodies in patients with advanced cutaneous melanoma (cMEL), squamous cell carcinoma of the skin (cSCC) or head and neck (hnSCC) and adenoid cystic carcinoma (ACC). Recruitment of the expansion part in melanoma patients is completed and preliminary results from this part are reported here. <h3>Methods</h3> Study CV-8102-008 is an open-label, cohort-based, dose escalation and expansion phase I study. Eight intratumoral injections of CV8102 are being administered initially over a 12-week period. The trial consists of two parts, a dose escalation part and an expansion part. Primary objective of the expansion part is to obtain additional safety data as well as initial estimates of efficacy in patients with advanced melanoma in a single agent cohort and patients with advanced melanoma patients refractory to anti-PD-1 therapy receiving CV8102 in combination with anti-PD-1 antibodies. In the expansion part, CV8102 was administered at a dose level of 600µg which has been determined as recommended phase 2 dose during the dose escalation part. <h3>Results</h3> As of January 2022 10 patients have been treated with CV8102 as a single agent and 30 patients have received CV8102 in combination with anti-PD-1 antibodies within the expansion part. Most frequent treatment emergent adverse events were mild to moderate fever, chills and asthenia. Regression of injected and distant noninjected lesions was observed (including 4 PR per RECIST 1.1. in the combination cohort). Preliminary safety and efficacy as well as selected biomarker results from the expansion cohorts will be presented. <h3>Conclusions</h3> The acceptable safety profile already observed during the dose escalation part could be confirmed in the expansion part. Preliminary evidence of clinical efficacy in the expansion cohorts was seen in combination with anti-PD-1-antibodies. <h3>Trial Registration</h3> NCT03291002 <h3>Ethics Approval</h3> The study was approved by central or local ethics committees depending on the country. In Germany: Central Ethics Committees in Tuebingen, Germany under 785/2016AMG1. In France: COMITE DE PROTECTION DES PERSONNES SUD-EST I under 2019-49, approval dated 17-May-2019. In Spain: CEC COMITÉ DE ÉTICA DE INVESTIGACIÓN CLÍNICA CON MEDICAMENTOS del Hospital Universitari Vall d’Hebron, Barcelona, approval date 28-Nov-2019 under the EUdraCT number. In Austria: Central Ethics Committee in Graz under 31-426 ex 18/19 approved on 19-Sep-2019. In the Russian Federation: ETHICS COMMITTEE AT FSBI ”NMRC OF ONCOLOGY n.a. N.N. BLOKHIN” OF THE MINISTRY OF HEALTHCARE OF THE RUSSIAN FEDERATION, INTERDISCIPLINARY ETHICS COMMITTEE of Omsk Region, Local Ethics Committee at FSAEI HE ”I.M. Sechenov First MSMU” of the Ministry of Healthcare of Russia (Sechenov University, Extract from Minutes № 03-21 of the scheduled meeting of the Local Ethics Committee dated 03 February 2021), BIOMEDICAL ETHICS COMMITTEE at N.I. PIROGOV CLINIC OF HIGH MEDICAL TECHNOLOGIES (IN-PATIENT AND OUTPATIENT FACILITIES), ST. PETERSBURG STATE UNIVERSITY (EXTRACT FROM MINUTES № 02/21 of the meeting of the Biomedical Ethics Committee), Ethics Committee at Federal State Budgetary Institution “National Medical Research Center of Oncology named after N. N. Petrov′′ of the Ministry of Health of the Russian Federation (Extract No. 5/130 from the Minutes of the regular session No. 8 of the Ethics Committee). <h3>Consent</h3> Written informed consent from the patient was obtained for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal." @default.
• W4308406944 created "2022-11-11" @default.
• W4308406944 creator A5004458225 @default.
• W4308406944 creator A5004881462 @default.
• W4308406944 creator A5005187138 @default.
• W4308406944 creator A5007525817 @default.
• W4308406944 creator A5015946065 @default.
• W4308406944 creator A5023198820 @default.
• W4308406944 creator A5025478490 @default.
• W4308406944 creator A5027768345 @default.
• W4308406944 creator A5033334588 @default.
• W4308406944 creator A5043771424 @default.
• W4308406944 creator A5047590296 @default.
• W4308406944 creator A5054698965 @default.
• W4308406944 creator A5056227404 @default.
• W4308406944 creator A5060671669 @default.
• W4308406944 creator A5060727011 @default.
• W4308406944 creator A5081539397 @default.
• W4308406944 creator A5084070841 @default.
• W4308406944 date "2022-11-01" @default.
• W4308406944 modified "2023-10-17" @default.
• W4308406944 title "786 Intratumorally administered CV8102 in patients with advanced solid tumors: preliminary results from ongoing expansion part in study 008" @default.
• W4308406944 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0786" @default.
• W4308406944 hasPublicationYear "2022" @default.
• W4308406944 type Work @default.
• W4308406944 citedByCount "0" @default.
• W4308406944 crossrefType "proceedings-article" @default.
• W4308406944 hasAuthorship W4308406944A5004458225 @default.
• W4308406944 hasAuthorship W4308406944A5004881462 @default.
• W4308406944 hasAuthorship W4308406944A5005187138 @default.
• W4308406944 hasAuthorship W4308406944A5007525817 @default.
• W4308406944 hasAuthorship W4308406944A5015946065 @default.
• W4308406944 hasAuthorship W4308406944A5023198820 @default.
• W4308406944 hasAuthorship W4308406944A5025478490 @default.
• W4308406944 hasAuthorship W4308406944A5027768345 @default.
• W4308406944 hasAuthorship W4308406944A5033334588 @default.
• W4308406944 hasAuthorship W4308406944A5043771424 @default.
• W4308406944 hasAuthorship W4308406944A5047590296 @default.
• W4308406944 hasAuthorship W4308406944A5054698965 @default.
• W4308406944 hasAuthorship W4308406944A5056227404 @default.
• W4308406944 hasAuthorship W4308406944A5060671669 @default.
• W4308406944 hasAuthorship W4308406944A5060727011 @default.
• W4308406944 hasAuthorship W4308406944A5081539397 @default.
• W4308406944 hasAuthorship W4308406944A5084070841 @default.
• W4308406944 hasBestOaLocation W43084069441 @default.
• W4308406944 hasConcept C121332964 @default.
• W4308406944 hasConcept C126322002 @default.
• W4308406944 hasConcept C141071460 @default.
• W4308406944 hasConcept C142424586 @default.
• W4308406944 hasConcept C143998085 @default.
• W4308406944 hasConcept C159654299 @default.
• W4308406944 hasConcept C203014093 @default.
• W4308406944 hasConcept C2777546739 @default.
• W4308406944 hasConcept C2777658100 @default.
• W4308406944 hasConcept C2779231225 @default.
• W4308406944 hasConcept C502942594 @default.
• W4308406944 hasConcept C71924100 @default.
• W4308406944 hasConcept C72563966 @default.
• W4308406944 hasConcept C87355193 @default.
• W4308406944 hasConcept C90924648 @default.
• W4308406944 hasConceptScore W4308406944C121332964 @default.
• W4308406944 hasConceptScore W4308406944C126322002 @default.
• W4308406944 hasConceptScore W4308406944C141071460 @default.
• W4308406944 hasConceptScore W4308406944C142424586 @default.
• W4308406944 hasConceptScore W4308406944C143998085 @default.
• W4308406944 hasConceptScore W4308406944C159654299 @default.
• W4308406944 hasConceptScore W4308406944C203014093 @default.
• W4308406944 hasConceptScore W4308406944C2777546739 @default.
• W4308406944 hasConceptScore W4308406944C2777658100 @default.
• W4308406944 hasConceptScore W4308406944C2779231225 @default.
• W4308406944 hasConceptScore W4308406944C502942594 @default.
• W4308406944 hasConceptScore W4308406944C71924100 @default.
• W4308406944 hasConceptScore W4308406944C72563966 @default.
• W4308406944 hasConceptScore W4308406944C87355193 @default.
• W4308406944 hasConceptScore W4308406944C90924648 @default.
• W4308406944 hasLocation W43084069441 @default.
• W4308406944 hasOpenAccess W4308406944 @default.
• W4308406944 hasPrimaryLocation W43084069441 @default.
• W4308406944 hasRelatedWork W2002120878 @default.
• W4308406944 hasRelatedWork W2003938723 @default.
• W4308406944 hasRelatedWork W2027742568 @default.
• W4308406944 hasRelatedWork W2047967234 @default.
• W4308406944 hasRelatedWork W2118496982 @default.
• W4308406944 hasRelatedWork W2351796763 @default.
• W4308406944 hasRelatedWork W2439875401 @default.
• W4308406944 hasRelatedWork W2528057197 @default.
• W4308406944 hasRelatedWork W4238867864 @default.
• W4308406944 hasRelatedWork W2525756941 @default.
• W4308406944 isParatext "false" @default.
• W4308406944 isRetracted "false" @default.
• W4308406944 workType "article" @default.